drugset / Trial / NCT04170530
Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and safety of mFOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC.
Timeline
- Start
- 2019-01-01
- Primary completion
- 2020-11-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 135 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 68 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |
Indications
No indication recorded.